Abbott Laboratories Company Info

Abbott Laboratories Company Info

An Abbott Laboratories Company Info guide, with links, news, and comments

Sorted by: Top Picks
From:   www.ap.org
Impax Laboratories Inc. confirmed Friday it is challenging the patents on Abbott Laboratories' cholesterol drug TriCor, and that Abbott is suing Impax for patent infringement. Impax, of Hayward, Calif., said it requested marketing approval for generic versions of 48 milligram and 145 milligram TriCor tablets. Abbott filed suit on Thursday in the U.S. District Court for the District of New Jersey. The lawsuit means the Food and Drug Administration cannot approve Impax's drug for 30 months, or until the litigation is resolved. Annual sales of TriCor, or fenofibrate, are more than $1 billion. The patents protecting TriCor will start to expire in January 2011, ... Read Full Story
From:   www.ap.org
Drug and medical-device company Abbott Laboratories is scheduled to reports earnings for the third quarter on Wednesday. The following is a summary of key developments and analyst opinion related to the period. OVERVIEW: Late last month Abbott announced it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay, a move that further expands the company's international scope and product portfolio. Abbott highlighted Solvay's access to emerging markets in Eastern Europe and Asia along with new products including hormone therapies and vaccines. The two companies previously shared marketing rights for Solvay's cholesterol drugs Trilipix and TriCor. Abbott has already snatched up ... Read Full Story
From:   www.ap.org
The Food and Drug Administration has approved a new test from Abbott Laboratories that detects both types of the virus that causes AIDS. The FDA says the company's Abbott Prism HIV O Plus test can detect HIV types 1 and 2. HIV type 2 is mostly found in West Africa, while HIV type 1 consists of various subgroups found in both the U.S. and West Africa. The test runs on North Chicago, Ill.-based Abbott's Prism system, an automated instrument also used to test blood for hepatitis. The new test will be used to screen for HIV in blood and organ donations. HIV attacks the ... Read Full Story
Written by sagitarius84 on
Abbott Laboratories engages in the development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Abbott Laboratories is a dividend aristocrat as well as a component of the S&P 500 index. It has been increasing its dividends for the past 36 consecutive years. Over the past 10 years the company has delivered an average total return of 8.50% annually to its loyal shareholders. The company has managed to deliver a 4.80% average annual increase in its EPS. The ROE has been declining over the past 10 years, from its highs in ... Read Full Story
From:   www.ap.org
Abbott Laboratories says second-quarter profit fell 3 percent, but the drug and medical-device company met Wall Street forecasts as the blockbuster drug Humira continued gaining ground in the market. The company earned $1.29 billion, or 83 cents per share, down from profit of $1.32 billion, or 85 cents per share, during the same period a year prior. Revenue rose 2.5 percent to $7.5 billion from $7.31 billion. Excluding charges, the company said it earned 89 cents per share, while Wall Street expected profit of 89 cents per share on revenue of $7.55 billion. Looking ahead, Abbott expects profit between 88 cents and 90 cents ... Read Full Story
Written by bullishbankers on
2008 was quite an interesting and exciting year for the Healthcare sector. Each sub-sector was struck with their own disruptions and it caused industry wide job cuts and strategic maneuvers. The Obama administration has come in and new legislation will be passed most likely hurting Biotechnology, Pharmaceuticals, and Managed Care. Only time will tell who stands on top after the talks of startling changes quickly dissipates. Nonetheless, I have provided you with three solid choices for your portfolio for 2009. Abbott Laboratories (ABT) By reading any of my recent articles you can promptly say that I am not a proud supporter of the Pharmaceuticals ... Read Full Story
Written by FreebieReporter on
By Abt Electronics Abt Electronics is offering an additional 5% off site wide. The sale prices are reflected on the product pages and in the shopping cart online. Some exclusions apply. Offer ends 10-12-09. Go to deal Read Full Story
Sorted by: Top Rated
No pictures yet.
Abbott Laboratories (NYSE: ABT) ended the last trading session at $51.31. So far the stock has hit a 52-week low of $41.27 and 52-week high of $57.40. Abbott Laboratories stock has been showing support around 50.28 and resistance in the 52.68 range. Technical indicators for the stock are Bullish and S&P gives ABT a positive 4 STAR (out of 5) buy rating. ABT appears on the Investors Observer Analysts Favorites list. For a hedged play on this...  
From marketintelligencecenter.com ()
Related news:
More perspectives...
Filed under: Earnings reports, Forecasts, Abbott Laboratories (ABT)Plenty of companies are reporting earnings this Wednesday morning, one of which is Abbott Laboratories (NYSE: ABT). The health-care giant reported third-quarter earnings of 95 cents per share, far better than last year's 69 cents per share. Taking items out of the equation, Abbott would have earned 92 cents per share, which is two cents better than the consensus estimate...  
From bloggingstocks.com ()
Related news:
More perspectives...
WASHINGTON, Nov 17 (Reuters) - The U.S. Food and Drug Administration, in an Aug 12 letter released on Tuesday: * Warned Abbott Laboratories about manufacturing ...  
From finanznachrichten.de ()
More perspectives...
(AP) — Abbott Laboratories said Thursday it is buying a potential chronic pain drug from PanGenetics BV for as much as $190 million. Abbott said the drug is in early-stage clinical testing as a treatment for pain cause by arthritis. If that trial is successful, Abbott may test it against ...  
From chicagobusiness.com ()
Related news:
More perspectives...
Visit StreetInsider.com at http://www.streetinsider.com/New+Coverage/Wedbush+Initiates+Coverage+on+Abbott+Laboratories+%28ABT%29+with+an+Outperform%3B+Fast-Expanding+Product+Mix+/5100046.html for the full story.  
From streetinsider.com ()
More perspectives...
Telegraph.co.ukJP Morgan, Intel, Abbott Laboratories in focusMarketWatchAbbott Laboratories said third-quarter net income rose 36.5% to $1.48 billion, or 95 cents a share, compared with $1.09 billion, or 69 cents a share, ...Market Update: Dow Enjoys Triple-Digit Gain on Strong DataSchaeffers ResearchCan New York stocks top 10000?Globe and MailUS HOT STOCKS: JPMorgan Chase, Conseco, IntelWall Street JournalistockAnalyst.com (press release...  
From news.google.com ()
Related news:
More perspectives...
Life Sciences , deals , pharma Ryan McBride wrote: There’s big news about Enlight Biosciences breaking here at the Xconomy Forum: Pharma’s Bet on Boston Innovation. Abbott Laboratories (NYSE: ABT ) has joined the consortium of big pharmas that  
From p.moreover.com ()
More perspectives...
Sponsors
Sorted by: Top Rated
No entries yet.
More From Zimbio
Copyright © 2009 - Zimbio, Inc. Some rights reserved.